AI-based medical imaging equipment firm Lunit has signed a contract to supply AI-based breast cancer screening solution “Lunit Insight MMG”
Fulvestrant Injection, 250 mg/5 mL, has an estimated market size of US $71 million for twelve months ending Sep 2022 according to IQVIA
The product is backed by required scientific proof and comparative bioequivalence studies
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
Results reinforce commitment to next-generation oral SERD development programme
In the next six months, the program aims to screen 4,000 women from underprivileged communities in and around Mathura
Transformation to pure-play Innovative Medicines company nears completion
Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments
Lynparza is the first and only approved PARPi targeting BRCA-mutated HER2-negative high-risk early breast cancer
Subscribe To Our Newsletter & Stay Updated
